NASDAQ:PRAX

Praxis Precision Medicines (PRAX) Stock Forecast, Price & News

$1.46

-0.03 (-2.01%)

(As of 09:52 AM ET)

Compare

Today's Range: $1.45
▼
$1.52
50-Day Range: $0.87
▼
$1.57
52-Week Range: $0.79
▼
$5.25

Volume: 10,229 shs
Average Volume: 1.36 million shs
Market Capitalization: $187.67 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $8.50

Praxis Precision Medicines MarketRank™ Forecast

Analyst Rating: Moderate Buy
2.75 Rating Score
Upside/Downside: 470.5% Upside
$8.50 Price Target
Short Interest: Healthy
2.12% of Shares Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: 0.62
Based on 4 Articles This Week
Insider Trading: Acquiring Shares
$10,600 Bought Last Quarter
Proj. Earnings Growth: Growing
From ($1.77) to ($1.33) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.21 out of 5 stars

Medical Sector

393rd out of 965 stocks

Pharmaceutical Preparations Industry

172nd out of 453 stocks

3.4

Analyst's Opinion

Consensus Rating
Praxis Precision Medicines has received a consensus rating of Moderate Buy. The company's average rating score is 2.75, and is based on 3 buy ratings, 1 hold rating, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $8.50, Praxis Precision Medicines has a forecasted upside of 470.5% from its current price of $1.49.
Amount of Analyst Coverage
Praxis Precision Medicines has only been the subject of 2 research reports in the past 90 days.

3.0

Short Interest

Percentage of Shares Shorted
2.12% of the outstanding shares of Praxis Precision Medicines have been sold short.
Short Interest Ratio / Days to Cover
Praxis Precision Medicines has a short interest ratio ("days to cover") of 2.3, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in Praxis Precision Medicines has recently increased by 10.57%, indicating that investor sentiment is decreasing significantly.

0.0

Dividend Strength

Dividend Yield
Praxis Precision Medicines does not currently pay a dividend.
Dividend Growth
Praxis Precision Medicines does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for PRAX.

2.6

News and Social Media Coverage

News Sentiment
Praxis Precision Medicines has a news sentiment score of 0.62. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.
News Coverage This Week
MarketBeat has tracked 4 news articles for Praxis Precision Medicines this week, compared to 1 article on an average week.
Search Interest
10 people have searched for PRAX on MarketBeat in the last 30 days. This is an increase of 11% compared to the previous 30 days.
MarketBeat Follows
Only 3 people have added Praxis Precision Medicines to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

1.7

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Praxis Precision Medicines insiders have bought more of their company's stock than they have sold. Specifically, they have bought $10,600.00 in company stock and sold $0.00 in company stock.
Percentage Held by Insiders
Only 4.90% of the stock of Praxis Precision Medicines is held by insiders.

1.3

Earnings and Valuation

Earnings Growth
Earnings for Praxis Precision Medicines are expected to grow in the coming year, from ($1.77) to ($1.33) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Praxis Precision Medicines is -0.49, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Praxis Precision Medicines is -0.49, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Praxis Precision Medicines has a P/B Ratio of 0.92. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Praxis Precision Medicines (NASDAQ:PRAX) Stock

Praxis Precision Medicines, Inc., a clinical-stage biopharmaceutical company, develops therapies for central nervous system disorders characterized by neuronal excitation-inhibition imbalance. It is developing ulixacaltamide, a small molecule inhibitor of T-type calcium channels that is in Phase IIb clinical trial for the treatment of essential tremor, as well as in Phase II clinical trial to treat Parkinson's disease; PRAX-562 for the treatment of pediatric patients with developmental and epileptic encephalopathies (DEE); and PRAX-628 to treat focal epilepsy. The company also develops PRAX-222 for the treatment of pediatric patients with early-onset SCN2A-DEE; PRAX-020 to treat KCNT1 related epilepsies; PRAX-080 for the treatment of PCDH19; and PRAX-090 and PRAX-100 for SYNGAP1 and SCN2A-LoF. It has a license agreement with RogCon Inc.; a research collaboration and license agreement with Ionis Pharmaceuticals, Inc.; a strategic collaboration and license agreement with UCB Biopharma SRL; and collaboration with The Florey Institute to develop three novel ASOs. Praxis Precision Medicines, Inc. was incorporated in 2015 and is based in Boston, Massachusetts.

PRAX Price History

30 days | 90 days | 365 days | Advanced Chart

PRAX Stock News Headlines

September 20, 2023 | americanbankingnews.com

Praxis Precision Medicines (NASDAQ:PRAX) Coverage Initiated by Analysts at Truist Financial

September 19, 2023 | msn.com

Truist Securities Initiates Coverage of Praxis Precision Medicines (PRAX) with Buy Recommendation

September 22, 2023 | Chaikin Analytics (Ad)

Buy This Stock for AI Tidal Wave (not NVDA)

The internet boom made more millionaires than any tech - Microsoft’s CEO says AI has even more potential. Here’s the #1 stock to buy.

September 7, 2023 | finance.yahoo.com

Praxis Precision Medicines to Present at H.C. Wainwright 25th Annual Global Investment Conference

August 31, 2023 | finance.yahoo.com

Praxis Precision Medicines to Present Data from Epilepsy Portfolio at the 35th International Epilepsy Congress

August 28, 2023 | finance.yahoo.com

Praxis Precision Medicines to Present Analyses of Patient-Focused, Clinically Meaningful Endpoints from Essential1 Study of Ulixacaltamide in Essential Tremor at the 2023 MDS International Congress

August 17, 2023 | finance.yahoo.com

Billionaire Steve Cohen Loads Up on These 2 ‘Strong Buy’ Penny Stocks — Here’s Why Wall Street Sees Over 500% Upside Potential

August 11, 2023 | finance.yahoo.com

The past year for Praxis Precision Medicines (NASDAQ:PRAX) investors has not been profitable

September 22, 2023 | Chaikin Analytics (Ad)

Buy This Stock for AI Tidal Wave (not NVDA)

The internet boom made more millionaires than any tech - Microsoft’s CEO says AI has even more potential. Here’s the #1 stock to buy.

August 10, 2023 | msn.com

HC Wainwright & Co. Maintains Praxis Precision Medicines (PRAX) Buy Recommendation

August 10, 2023 | markets.businessinsider.com

What 5 Analyst Ratings Have To Say About Praxis Precision Medicine

August 9, 2023 | markets.businessinsider.com

H.C. Wainwright Remains a Buy on Praxis Precision Medicines (PRAX)

August 9, 2023 | finance.yahoo.com

Praxis Precision Medicines Provides Corporate Update and Reports Second Quarter 2023 Financial Results

August 8, 2023 | msn.com

Praxis reports positive data from study of focal epilepsy drug

August 8, 2023 | finance.yahoo.com

Praxis Precision Medicines Announces Positive Data from Randomized Withdrawal Sub-Study and Long-Term Extension of Essential1 Study for Ulixacaltamide

August 7, 2023 | finance.yahoo.com

Praxis Precision Medicines Announces Positive Results of EEG Analysis of PRAX-628 Phase 1 Study

August 3, 2023 | finance.yahoo.com

Praxis Precision Medicines to Participate at the 2023 Wedbush PacGrow Healthcare Conference

July 24, 2023 | msn.com

Praxis Precision Medicines: Long List Of Failures And Mixed Data

July 14, 2023 | finance.yahoo.com

Following a 63% decline over last year, recent gains may please Praxis Precision Medicines, Inc. (NASDAQ:PRAX) institutional owners

July 6, 2023 | msn.com

Praxis Precision Medicines (PRAX) Price Target Decreased by 11.23% to 8.26

June 28, 2023 | nasdaq.com

Cohen's Point72 Boosts Stake in Praxis Precision Medicines Ahead of Phase 3 Trials

June 26, 2023 | benzinga.com

Steven A. Cohen Discloses 8.9% Passive Stake In Praxis Precision Medicines

June 22, 2023 | finanznachrichten.de

Praxis Precision Medicines, Inc.: Praxis Precision Medicines Announces Closing of Financing and Reiterates Corporate Priorities

June 22, 2023 | finance.yahoo.com

Praxis Precision Medicines Announces Closing of Financing and Reiterates Corporate Priorities

June 20, 2023 | markets.businessinsider.com

Wedbush Sticks to Their Hold Rating for Praxis Precision Medicines (PRAX)

June 17, 2023 | msn.com

Praxis Precision Medicines stock dips on pricing $59.1M securities offering

June 16, 2023 | finance.yahoo.com

Praxis Precision Medicines, Inc. Announces Pricing of $59.1 Million Public Offering

See More Headlines

Receive PRAX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Praxis Precision Medicines and its competitors with MarketBeat's FREE daily newsletter.

PRAX Company Calendar

Last Earnings: 8/09/2023
Today: 9/21/2023
Next Earnings (Estimated): 11/08/2023
Fiscal Year End: 12/31/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:PRAX
CUSIP: N/A
CIK: 1689548
Web: www.praxismedicines.com
Phone: 617-300-8460
Fax: N/A
Employees: 109
Year Founded: N/A

Price Target and Rating

Average Stock Price Forecast: $8.50
High Stock Price Forecast: $10.00
Low Stock Price Forecast: $7.00
Forecasted Upside/Downside: +470.5%
Consensus Rating: Moderate Buy
Rating Score (0-4): 2.75
Research Coverage: 4 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($3.03)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-214,030,000.00
Net Margins: N/A
Pretax Margin: -10,716.19%
Return on Equity: -178.60%
Return on Assets: -129.68%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 5.31
Quick Ratio: 5.31

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $1.62 per share
Price / Book: 0.92

Miscellaneous

Outstanding Shares: 128,540,000
Free Float: 122,242,000
Market Cap: $191.52 million
Optionable: Not Optionable
Beta: 2.93

Elon Musk's Next Move

Wondering when you'll finally be able to invest in SpaceX, StarLink or The Boring Company? Click the link below to learn when Elon Musk will let these companies finally IPO.

Get This Free Report

Key Executives

Mr. Marcio Souza M.B.A. (Age 44)
Pres, CEO & Director
Comp: $1.04M

Mr. Timothy Edwin Kelly (Age 49)
CFO & Treasurer
Comp: $633.49k

Dr. Steven Petrou B.Sc. (Hons.)
Ph.D., Co-Founder & Chief Scientific Officer

Lauren Mastrocola
VP of Fin. & Principal Accounting Officer

Dr. Karl Hansen Ph.D.
Chief Technical Operations Officer

Alex Kane
VP of Investor Relations & Corp. Communications

Mr. Alex Nemiroff J.D. (Age 44)
Gen. Counsel & Sec.

Ms. Kelly McCue
Chief People Officer

Ms. Alyssa J. S. Wyant (Age 48)
Chief Regulatory & Quality Officer

Ms. Megan T. Sniecinski (Age 41)
Chief Bus. Officer

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

PRAX Stock - Frequently Asked Questions

Should I buy or sell Praxis Precision Medicines stock right now?: 4 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Praxis Precision Medicines in the last year. There are currently 1 hold rating and 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" PRAX shares.
View PRAX analyst ratings or view top-rated stocks.
What is Praxis Precision Medicines' stock price forecast for 2023?: 4 equities research analysts have issued 1-year price targets for Praxis Precision Medicines' stock. Their PRAX share price forecasts range from $7.00 to $10.00. On average, they expect the company's share price to reach $8.50 in the next year. This suggests a possible upside of 470.5% from the stock's current price.
View analysts price targets for PRAX or view top-rated stocks among Wall Street analysts.
How have PRAX shares performed in 2023?: Praxis Precision Medicines' stock was trading at $2.38 at the beginning of 2023. Since then, PRAX shares have decreased by 37.4% and is now trading at $1.49.
View the best growth stocks for 2023 here.
When is Praxis Precision Medicines' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Wednesday, November 8th 2023.
View our PRAX earnings forecast.
How were Praxis Precision Medicines' earnings last quarter?: Praxis Precision Medicines, Inc. (NASDAQ:PRAX) posted its earnings results on Wednesday, August, 9th. The company reported ($0.49) earnings per share for the quarter, beating analysts' consensus estimates of ($0.66) by $0.17. The firm had revenue of $0.78 million for the quarter.
When did Praxis Precision Medicines IPO?: (PRAX) raised $126 million in an initial public offering (IPO) on Friday, October 16th 2020. The company issued 7,400,000 shares at $16.00-$18.00 per share. Cowen, Evercore ISI, Piper Sandler and Wedbush PacGrow acted as the underwriters for the IPO and Blackstone Capital Markets was co-manager.

What is Praxis Precision Medicines' stock symbol?: Praxis Precision Medicines trades on the NASDAQ under the ticker symbol "PRAX."
Who are Praxis Precision Medicines' major shareholders?: Praxis Precision Medicines' stock is owned by many different retail and institutional investors. Top institutional shareholders include Point72 Asset Management L.P. (16.46%), Cormorant Asset Management LP (14.82%), Sphera Funds Management LTD. (13.68%), VR Adviser LLC (8.28%), Silverarc Capital Management LLC (5.42%) and Acadian Asset Management LLC (2.41%). Insiders that own company stock include Alex Nemiroff, Dean J Mitchell, Lauren Mastrocola, Marcio Souza, Parallel Master Fund LP Bsof and Timothy Edwin Kelly.
View institutional ownership trends.
How do I buy shares of Praxis Precision Medicines?: Shares of PRAX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is Praxis Precision Medicines' stock price today?: One share of PRAX stock can currently be purchased for approximately $1.49.
How much money does Praxis Precision Medicines make?: Praxis Precision Medicines (NASDAQ:PRAX) has a market capitalization of $191.52 million. The company earns $-214,030,000.00 in net income (profit) each year or ($3.03) on an earnings per share basis.
How many employees does Praxis Precision Medicines have?: The company employs 109 workers across the globe.
How can I contact Praxis Precision Medicines?: Praxis Precision Medicines' mailing address is 101 MAIN STREET #1210, CAMBRIDGE MA, 02142. The official website for the company is www.praxismedicines.com. The company can be reached via phone at 617-300-8460 or via email at investors@praxismedicines.com.

This page (NASDAQ:PRAX) was last updated on 9/22/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial